Search

Your search keyword '"İdilman, R."' showing total 49 results

Search Constraints

Start Over You searched for: Author "İdilman, R." Remove constraint Author: "İdilman, R." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
49 results on '"İdilman, R."'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

2. A global research priority agenda to advance public health responses to fatty liver disease

3. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

4. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

5. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

6. Global multi-stakeholder endorsement of the MAFLD definition

7. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

8. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

9. Advancing the global public health agenda for NAFLD: a consensus statement

10. Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome

11. Low serum albumin at admission is associated with mortality among inpatients with cirrhosis: a multi-national experience

12. Global multi-stakeholder endorsement of the MAFLD definition

13. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

14. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

15. Assessing hepatic steatosis by magnetic resonance in potential living liver donors

16. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.

17. A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis.

18. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.

19. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.

20. Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!

21. Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study.

22. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

23. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.

24. Demonstration of therapy response to radioembolization with 90 Y resin microspheres on 68 Ga-PSMA PET/MRI in a patient with hepatocellular carcinoma.

25. Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.

26. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.

27. Diagnosis and Treatment of Autoimmune Hepatitis: Questions, Answers, and Illustrative Cases: Endorsed by Autoimmune Liver Diseases Special Interest Group, Turkish Association for the Study of Liver.

28. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.

29. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.

30. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

31. Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium.

32. Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta.

33. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.

34. Determining Subclinical Cardiovascular and Cardiac Diseases in Patients with Non-Alcoholic Fatty Liver Disease.

35. Management of Biliary Complications in Liver Transplant Recipients with Duct-To-Duct Anastomosis: A Single-Center Experience.

36. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.

37. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study.

39. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.

40. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.

41. Characteristics of patients with hepatocellular carcinoma: A multicenter study.

43. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.

44. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.

45. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.

46. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.

47. Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting.

48. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study.

49. Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery.

Catalog

Books, media, physical & digital resources